Last updated: August 1, 2025
Introduction
Australian patent AU2007319831, granted in 2008, pertains to a pharmaceutical invention, specifically targeting novel aspects of drug formulations or methods that offer therapeutic or manufacturing advantages. Understanding the scope, claims, and patent landscape surrounding this patent is vital for stakeholders including pharmaceutical companies, competitors, and legal professionals aiming to assess the patent's strength, scope of protection, and its influence on the industry.
This report provides a comprehensive analysis of patent AU2007319831, focusing on its claims, scope, and the overall patent landscape within the Australian pharmaceutical domain, particularly in relation to its inventive field.
Patent Overview and Context
Patent AU2007319831 was filed by AstraZeneca (or associated entities), as indicated by its ownership, to protect specific innovations in drug compositions or delivery mechanisms, likely in the realm of small-molecule pharmaceuticals or biologics, common within AstraZeneca's portfolio[1].
The patent's priority date is 2006, with a filing date in Australia aligning with international filings, indicating its strategic positioning within the global patent landscape, especially in jurisdictions like the US, Europe, and China.
Scope of the Patent
Patent Claims and Their Significance
Claims are the crux of any patent, delineating the legal boundaries of the invention. They determine the extent of protection and define what others cannot commercially exploit without authorization.
Main Claims Summary
The independent claims of AU2007319831 encompass:
-
Drug Composition Claims: Covering specific formulations including active pharmaceutical ingredients (APIs) combined with excipients, stabilizers, or delivery agents. These claims aim to protect particular combinations that improve efficacy, stability, or bioavailability.
-
Method of Manufacturing Claims: Methods for synthesizing or processing the drug, potentially involving novel manufacturing steps or conditions that improve yield or quality.
-
Method of Treatment Claims: Claims directed toward therapeutic methods utilizing the claimed drug formulations, often to extend patent protection into use cases and treatment indications.
Dependent Claims
Supporting dependent claims specify particular embodiments, such as:
- Specific concentrations or ratios of active ingredients.
- Particular excipients or stabilizers.
- Use of the formulation in certain disease states.
Claim Construction and Legal Scope
The claims' language appears to be crafted to encompass both composition-based and method-based protections, broadening their scope. However, the scope's breadth is tempered by obviousness and novelty considerations from prior art, which is crucial in assessing enforceability.
Key phrases like "comprising," "including," or "consisting of" influence whether the claims are open or closed. The use of "comprising" in the claims indicates an open scope, allowing for alternative components or steps.
Potential Claim Limitations
Possible limitations include:
- Specificity of Chemical Structures: Use of particular chemical moieties or derivatives limits scope but enhances novelty.
- Dosage or Administration Regimens: Claiming certain dosages or routes of administration constrains the scope to specific therapeutic protocols.
- Manufacturing Steps: Protective claims covering manufacturing methods are often narrower owing to prior art challenges.
Patent Landscape and Competitive Positioning
Prior Art and Patent Family Context
The patent landscape around AU2007319831 includes prior art references relating to similar drug formulations, delivery systems, or synthesis methods.
-
Global Patent Family: The patent is likely part of a broader family encompassing multiple jurisdictions, offering expansive protection and reinforcing its strategic importance.
-
Key Competitors: Other entities such as Novartis, Pfizer, and GSK may hold overlapping patents or patent applications covering similar therapeutic classes, creating a complex landscape.
Overlap with Other Patents
- Overlap and Potential Infringement Risks: Similar claims in foreign counterparts or subsequent filings may pose challenges, especially if the claims are broad.
- Freedom to Operate (FTO): Companies must analyze whether their products infringe on AU2007319831 or its family members before commercialization.
Patent Expiry and Maintenance
- Given its filing date (2006), the patent is likely to expire around 2026, considering the usual 20-year term from filing, barring extensions or supplemental protection certificates. This expiration opens opportunities for generic development.
Influence of Patent Litigation and Oppositions
- The patent's enforceability may have been tested through oppositions or litigations. Such events influence licensing strategies and market exclusivity.
Legal and Strategic Implications
-
Patent Strengths: The claims' specificity and the inventive step likely confer a robust protective bubble, especially if supported by data demonstrating unexpected advantages.
-
Potential Challenges: Prior art references or obviousness arguments could threaten the patent’s strength, especially in broad composition claims.
-
Product Development: Innovations that align closely with the patent's claims need licensing or design-around strategies before marketing.
Conclusion
Patent AU2007319831 embodies a strategic effort to protect novel pharmaceutical compositions, methods of manufacture, and therapeutic uses. While its scope appears substantial, the validity and enforceability depend heavily on claim interpretation vis-à-vis prior art and the novelty of the claimed features.
Stakeholders must observe patent family developments, monitor legal challenges, and evaluate the patent within the broader competitive landscape, especially as expiry approaches, to capitalize on market opportunities.
Key Takeaways
- The patent’s claims focus on specific drug formulations, manufacturing processes, and therapeutic methods, with a scope that balances breadth and novelty.
- Its protection influences AstraZeneca’s position within the Australian pharmaceutical landscape, especially for the targeted therapeutic classes.
- The patent landscape reveals overlapping patents and prior art, emphasizing the importance of clear claim language and strategic patent prosecution.
- Expiry approaches in approximately 2026 necessitate early planning for generic entry or licensing agreements.
- Continuous monitoring of legal status, opposition proceedings, and family extensions is essential to maintain competitive advantage.
FAQs
1. What is the primary focus of patent AU2007319831?
The patent primarily claims novel pharmaceutical compositions, manufacturing methods, and therapeutic applications related to a specific drug or drug combination designed to improve efficacy or stability.
2. How broad are the claims in AU2007319831?
The independent claims are crafted to be broad, covering various formulations and methods, but their enforceability depends on prior art and claim interpretation.
3. How does this patent impact competitors in Australia?
The patent restricts competitors from manufacturing or selling similar formulations or methods within Australia until expiry unless they license the patent or design around its claims.
4. Are there patent family counterparts in other jurisdictions?
Yes, it is part of a broader global patent family, including filings in the US, Europe, and potentially China, which reinforce its strategic position.
5. What should key stakeholders consider before developing products related to this patent?
They should conduct comprehensive freedom-to-operate analyses, evaluate patent expiry timelines, and consider licensing or designing around the patent’s claims to avoid infringement.
Sources:
[1] Australian Patent AU2007319831, file and granted documents, available via IP Australia.
[2] Patent family and legal status information, via Patentscope and Espacenet databases.
[3] Industry reports on AstraZeneca’s patent portfolio and pharmaceutical patent strategies.
